scholarly journals NMDA and Non-NMDA Ionotropic Glutamate Receptors Modulate Striatal Acetylcholine Release via Pre- and Postsynaptic Mechanisms

2002 ◽  
Vol 71 (5) ◽  
pp. 2006-2017 ◽  
Author(s):  
M. Morari ◽  
S. Sbrenna ◽  
M. Marti ◽  
F. Caliari ◽  
C. Bianchi ◽  
...  
Keyword(s):  
Glutamate Receptors ◽  
Acetylcholine Release ◽  
Ionotropic Glutamate Receptors

Glycine agonism in ionotropic glutamate receptors

2021 ◽  
pp. 108631
Author(s):  
David Stroebel ◽  
Laetitia Mony ◽  
Pierre Paoletti
Keyword(s):  
Glutamate Receptors ◽  
Ionotropic Glutamate Receptors

Preparation of domoic acid analogues using a bioconversion system, and their toxicity in mice

2021 ◽  
Author(s):  
Yukari Maeno ◽  
Yuichi Kotaki ◽  
Ryuta Terada ◽  
Masafumi Hidaka ◽  
Yuko Cho ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Chemical Synthesis ◽  
Glutamate Receptors ◽  
Domoic Acid ◽  
Ionotropic Glutamate Receptors ◽  
The Central Nervous System ◽  
Potent Agonist

Domoic acid (1, DA), a member of the natural kainoid family, is a potent agonist of ionotropic glutamate receptors in the central nervous system. The chemical synthesis of DA and...

scholarly journals NMDA and AMPA Receptor Autoantibodies in Brain Disorders: From Molecular Mechanisms to Clinical Features

Cells ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 77
Author(s):  
Fabrizio Gardoni ◽  
Jennifer Stanic ◽  
Diego Scheggia ◽  
Alberto Benussi ◽  
Barbara Borroni ◽  
...  
Keyword(s):  
Glutamate Receptors ◽  
Ampa Receptor ◽  
Molecular Mechanisms ◽  
Clinical Symptoms ◽  
In Vivo Studies ◽  
Ionotropic Glutamate Receptors ◽  
Brain Disorders ◽  
Functional Impairments ◽  
Different Types

The role of autoimmunity in central nervous system (CNS) disorders is rapidly expanding. In the last twenty years, different types of autoantibodies targeting subunits of ionotropic glutamate receptors have been found in a variety of patients affected by brain disorders. Several of these antibodies are directed against NMDA receptors (NMDAR), mostly in autoimmune encephalitis, whereas a growing field of research has identified antibodies against AMPA receptor (AMPAR) subunits in patients with different types of epilepsy or frontotemporal dementia. Several in vitro and in vivo studies performed in the last decade have dramatically improved our understanding of the molecular and functional effects induced by both NMDAR and AMPAR autoantibodies at the excitatory glutamatergic synapse and, consequently, their possible role in the onset of clinical symptoms. In particular, the method by which autoantibodies can modulate the localization at synapses of specific target subunits leading to functional impairments and behavioral alterations has been well addressed in animal studies. Overall, these preclinical studies have opened new avenues for the development of novel pharmacological treatments specifically targeting the synaptic activation of ionotropic glutamate receptors.

Sign in / Sign up

Export Citation Format

Share Document